Current status of safinamide for the drug portfolio of Parkinson's disease therapy.

Current status of safinamide for the drug portfolio of Parkinson's disease therapy.

Item
http://www.wikidata.org/entity/Q38140018
Emerging approaches in Parkinson's disease - adjunctive role of safinamideSafinamide for the treatment of Parkinson's disease.Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.Rational drug discovery design approaches for treating Parkinson's disease.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson's disease.Parkinson's disease, antiparkinson medicines, and driving.Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective.Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
P2860

Current status of safinamide for the drug portfolio of Parkinson's disease therapy.

Item
http://www.wikidata.org/entity/Q38140018
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
@en
type
label
Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
@en
prefLabel
Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
@en
P1433
P1476
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
@en
P2860
P304
P31
P356
10.1586/14737175.2013.827488
P433
P478
P50
P577
P698
P921